Clinical Trial Update: Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update comparing TPC+Apatinib+Camrelizumab versus GP+Camrelizumab in high-risk nasopharyngeal carcinoma to assess efficacy and safety; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Apatinib (apatinib)
• CISPLATIN (cisplatin)
• Camrelizumab (camrelizumab)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: XIANG YANQUN | Conditions: Nasopharyngeal Carcinoma | Phase 3 | Status: RECRUITING